Pages that link to "Q35947805"

The following pages link to Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies (Q35947805):

Displaying 19 items.

• Interactions between Lipids and Human Anti-HIV Antibody 4E10 Can Be Reduced without Ablating Neutralizing Activity (Q27658138) (← links)
• International network for comparison of HIV neutralization assays: the NeutNet report II (Q28730045) (← links)
• International network for comparison of HIV neutralization assays: the NeutNet report (Q33410826) (← links)
• Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors (Q33725673) (← links)
• High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutraliz (Q33920519) (← links)
• Increased sensitivity to broadly neutralizing antibodies of end-stage disease R5 HIV-1 correlates with evolution in Env glycosylation and charge (Q33941033) (← links)
• HIV-1 envelope glycoprotein resistance to monoclonal antibody 2G12 is subject-specific and context-dependent in macaques and humans (Q34990575) (← links)
• Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic (Q35077704) (← links)
• Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies (Q35077797) (← links)
• Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity (Q35826458) (← links)
• Cross-reactive broadly neutralizing antibodies: timing is everything (Q36105782) (← links)
• Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones (Q36532973) (← links)
• Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection (Q36845710) (← links)
• Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. (Q36974754) (← links)
• HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds (Q37073506) (← links)
• HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity. (Q37360774) (← links)
• HIV-1 blocks the signaling adaptor MAVS to evade antiviral host defense after sensing of abortive HIV-1 RNA by the host helicase DDX3. (Q40395105) (← links)
• Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection (Q44176443) (← links)
• Escape from autologous humoral immunity of HIV-1 is not associated with a decrease in replicative capacity. (Q44775993) (← links)